A Randomized, Multicenter Clinical Trial to Determine the Efficacy, Safety and Tolerability of Peg-filgrastim (Gema) Compared to Peg-filgrastim (Roche) for Prevention of Chemotherapy Induced Neutropenia in Patients With Breast Cancer
试验速览
- 阶段
- 3 期
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Clinical Efficacy: Duration (in days) of severe neutropenia-DSN
研究概览
简要总结
This is a randomized, multicentre, Phase 3 study. Patients will be randomly assigned to the Study drug or its comparator. The study will be blinded for the staff members in charge of the endpoint assessment.
详细描述
Eligible patients will be scheduled to receive a chemotherapy regimen with risk of febrile neutropenia ≥20%. Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMA BIOTECH, or Peg-Filgrastim of Roche).
A total of 4 or 6 cycles of chemotherapy supported by Peg-Filgrastim will be administered with an interval of three weeks between each cycle.
Patients will be followed up for 28± 3 days after the last dose of Peg-Filgrastim.
Hematological assessment (Absolute Neutrophil Count [ANC]) will be assessed on day 1 or up to -3 (before administration of anticancer chemotherapy), day 2 or 3 and 5 through 9 of the first cycle, and thereafter every day until post-nadir ANC recovery to ≥ 1.5 x 109/l following each cycle of chemotherapy. In the following cycles, hematological assessment shall be performed on day 1 or up to -3 (before administration of anticancer chemotherapy), on day 2 or 3 and on days 5 and 7. This schedule only applies if the subject did not develop Severe Neutropenia on the previous cycle. If the patient develops Severe Neutropenia on the first cycle or at any cycle, then the schedule corresponding to first cycle shall be followed.
During baseline (before the administration of Peg-Filgrastim), day 5 and day 9 following the first cycle of chemotherapy CD34+ (cluster of differentiation) count will be determined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female patients aged 18 to 70 years old.
- •Patients diagnosed having high risk stage 2 or stage 3 or 4 of breast cancer (by histopathological or cytological diagnosis) and need neoadjuvant, adjuvant chemotherapy, or with metastatic disease.
- •A priori has been decided to be treated with Peg-Filgrastim and subjects eligible for Peg-Filgrastim therapy according to indications and clinical use in the product monograph
- •Patients scheduled to receive 4 or 6 cycles of chemotherapy (Taxane combinations) with prophylactic Peg-Filgrastim at 3 weeks interval. Monoclonal Antibodies in addition to Taxane regimens are permitted.
- •Any acute adverse effects of prior therapy must have resolved to ≤ NCI CTCAE (Version 4.0) grade 1 (excluding alopecia) prior to Day 1 of Cycle 1
- •Eastern Cooperative Oncology Group - ECOG Performance Status 0, 1 or 2 as determined on Day 1 or up to -3 of Cycle 1 prior to administration of chemotherapy
- •Patients must have adequate organ function including the following:
- •Adequate bone marrow functions, as determined within 3 days prior to administration of chemotherapy on Day 1 of Cycle 1 and as indicated by Hb ≥9,5 g/dl (transfusion permitted to be included in the trial ),WBC (white blood cell) ≥3,5 x 109/l, Absolute neutrophil count (ANC) ≥1.5 x 109/l, Platelets ≥95 x 109/l;
- •Adequate renal and hepatic function, as determined within 3 days prior to administration of chemotherapy on Day 1 of Cycle 1 and defined as follows,
- •Hepatic: Bilirubin ≤ 1.5 x the upper limit of normal (ULN) (unless elevation is known to be due to Gilbert's disease), Subjects must also meet one of the following criteria:
- •Alkaline phosphatase within normal reference range and both AST (aspartate aminotransferase) and ALT (alanine aminotransferase) >2.5 x ULN; or
- •Alkaline phosphatase <2.5 x ULN and both AST and ALT <1.5 x ULN; or
- •Alkaline phosphatase <5 x ULN and both AST and ALT within normal reference range;
- •Renal: Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≤ 60 ml/min (calculated according to the Cockcroft and Gault formula)
- •Patients of child-bearing potential must have a negative pregnancy test within 3 days prior to the first dose of chemotherapy and at day 1 or up to -3 days of each Cycle) and use at least one form of contraception as approved by the investigator during the study.
- •Life expectancy >6 months
排除标准
- •Safety of treatment dependent criteria:
- •Presence of any serious concomitant systemic disorders incompatible with the administration of filgrastim, Peg-Filgrastim or any systemic disease that can influence the patient's safety according to doctor's diagnosis.
- •History of hypersensitivity to Peg-Filgrastim, filgrastim or E.coli derived proteins.
- •Serious local infection or active systemic infection within 10 days prior to enrollment or patients who have taken antibiotics within the previous 10 days
- •Pregnant or breast-feeding patients
- •Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV)
- •Known bleeding disorder
- •Patient known to have HIV, Hepatitis B, Hepatitis C or who have a positive serology for HIV, Hepatitis B or Hepatitis C at screening
- •History or presence of sickle cell disease
- •Concurrent or prior radiotherapy within four weeks of randomization
- •Criteria dependent on compliance with study procedures, or the evaluation of the response:
- •Unwilling to use a reliable and acceptable contraceptive method throughout the study period (fertile patients only)
- •Treatment with certain other agents to treat the malignant disease
- •Known drug addiction, including alcoholism
- •Treatment with any investigational product within 30 days prior to study drug administration
- •Concurrent prophylactic antibiotics
- •Previous participation in this study.
- •Already involved in another trial.
- •History of bone marrow or stem cell transplantation.
- •Previous therapy should not have included G-CSF (granulocyte-colony stimulating factor)
- •Previous participation in this study: Subjects who are considered screening failures are allowed to be re-screened, except if have started chemotherapy. In case of re-screening the following assessments and evaluations do not have to be repeated: Demographics, Medical history, HIV, Hepatitis B and C serology.
研究组 & 干预措施
Peg-Neutropine®
Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
干预措施: Peg-Filgrastim (Drug)
Neulastim®
Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
干预措施: Peg-Filgrastim (Drug)
结局指标
主要结局
Clinical Efficacy: Duration (in days) of severe neutropenia-DSN
时间窗: Day 5 to day 9 of the first cycle
ANC (Absolute Neutrophil Count) \< 500/mm3 in the first cycle of chemotherapy.
次要结局
- infections(Day 5 to Day 21 during 4 - 6 cycles)
- IV anti-infectives(Day 5 to Day 21 during 4 - 6 cycles)
- ANC nadir(Day 5 to Day 21 during 4 - 6 cycles)
- Clinical Efficacy: Incidence of severe neutropenia(Day 5 to Day 21 during 4 - 6 cycles)
- Incidence of neutropenia(Day 5 to Day 21 during 4 - 6 cycles)
- Hospitalization due to neutropenia(Day 5 to Day 21 during 4 - 6 cycles)
- Fever(Day 5 to Day 21 during 4 - 6 cycles)
- Post-chemotherapy hospitalization(Day 5 to Day 21 during 4 - 6 cycles)
- Mortality(Day 5 to Day 21 during 4 - 6 cycles)
- Pharmacodynamics(Day 5 and 9 of the first cycle)
- Incidence of Adverse Drug Reactions (safety and tolerability) as assessed by CTCAE v4.0(Day 5 to Day 21 during 4 - 6 cycles)
- Immunogenicity(Day 5 and Day 28 of the last cycle)